Table 2.
Association between RSPO2 rs555008 and clinical outcomes among mCRC patients according to KRAS status
| Tumor response | Progression-free survival | Overall survival | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genotype | N | Yes | No | Chi- square test P value | Median (95%CI), months | HR (95%CI) | Log-rank test P value | Adjusted HR (95%CI) a | Wald test P value | Median (95%CI), months | HR (95%CI) | Log-rank test P value | Adjusted HR (95%CI) a | Wald test P value | |
| KRAS wild-type | |||||||||||||||
| Training cohort | T/T | 121 | 69(63.3%) | 40(36.7%) | 0.44 | 10.1(9.0,12.0) | Reference | 0.16 | Reference | 0.44 | 22.3(17.5,26.4) | Reference | 0.011 | Reference | 0.15 |
| Any G | 91 | 57(68.7%) | 26(31.3%) | 11.5(9.6,13.0) | 0.81(0.59,1.09) | 0.88(0.64,1.22) | 28.4(22.7,35.0) | 0.64(0.45,0.90) | 0.76(0.52,1.11) | ||||||
| Validation cohort | T/T | 48 | 29(61.7%) | 18(38.3%) | 0.64 | 9.0(7.6,11.0) | Reference | 0.17 | Reference | 0.29 | 23.3(14.6,26.9) | Reference | 0.046 | Reference | 0.012 |
| Any G | 38 | 24(66.7%) | 12(33.3%) | 11.6(9.9,12.7) | 0.72(0.44,1.17) | 0.74(0.43,1.28) | 36.0(23.9,48.7) | 0.62(0.38,1.00) | 0.49(0.28,0.86) | ||||||
| Control cohort | T/T | 105 | 65(75.6%) | 21(24.4%) | 0.42 | 10.1(8.5,11.3) | Reference | 0.74 | Reference | 0.66 | 36.4(21.9,39.4) | Reference | 0.46 | Reference | 0.46 |
| Any G | 121 | 76(70.4%) | 32(29.6%) | 10.0(8.3,12.2) | 1.05(0.79,1.40) | 1.07(0.80,1.43) | 27.6(22.5,33.8) | 1.14(0.80,1.63) | 1.15(0.80,1.65) | ||||||
| KRAS mutant | |||||||||||||||
| Training cohort | T/T | 23 | 9(40.9%) | 13(59.1%) | 0.45 | 11.2(8.3,14.7) | Reference | 0.023 | Reference | 0.099 | 26.3(18.2,36.0) | Reference | 0.076 | Reference | 0.057 |
| Any G | 19 | 10(52.6%) | 9(47.4%) | 8.1(6.1,12.3) | 1.93(0.98,3.79) | 1.98(0.88,4.45) | 16.5(12.5,25.1) | 1.75(0.91,3.36) | 2.58(0.97,6.87) | ||||||
| Validation cohort | T/T | 60 | 33(55.9%) | 26(44.1%) | 0.60 | 10.3(8.8,13.0) | Reference | 0.009 | Reference | 0.027 | 27.9(20.8,38.3) | Reference | 0.10 | Reference | 0.59 |
| Any G | 28 | 14(50.0%) | 14(50.0%) | 8.7(7.8,9.5) | 1.91(1.12,3.28) | 1.99(1.08,3.65) | 19.8(15.6,26.3) | 1.52(0.91,2.56) | 1.17(0.66,2.06) | ||||||
a
Based on the multivariable Cox proportional hazards regression model adjusting for sex, age, ECOG performance status, primary tumor site, liver limited metastases, primary tumor resection, adjuvant chemotherapy, and BRAF status in the training and control cohorts; adjusting for sex, age, ECOG performance status, primary tumor site, number of metastatic sites, primary tumor resection, and BRAF status in the validation set.